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Background: Previous studies have shown that elosulfase 
alfa has a favorable efficacy/safety profile in Morquio A patients 
aged ≥5 y. This study evaluated safety and impact on urine 
keratan sulfate (uKS) levels and growth velocity in younger 
patients.
Methods: Fifteen Morquio A patients aged <5 y received 
elosulfase alfa 2.0 mg/kg/week for 52 wk during the primary 
treatment phase of a phase II, open-label, multinational study. 
Primary endpoint was safety and tolerability; secondary end-
points were change in uKS and growth velocity over 52 wk.
results: All 15 patients completed the primary treatment 
phase. Six of 743 infusions (0.8%) administered led to adverse 
events (AEs) requiring infusion interruption and medical inter-
vention. Eleven patients (73.3%) had ≥1 study drug-related AE, 
mostly infusion-associated reactions. Mean z-score growth 
rate per year numerically improved from −0.6 at baseline to 
−0.4 at week 52. Comparison to untreated subjects of simi-
lar age in the Morquio A Clinical Assessment Program study 
showed a smaller decrease in height z-scores for treated than 
for untreated patients. Mean percent change from baseline in 
uKS was −30.2% at 2 wk and −43.5% at 52 wk.
conclusion: Early intervention with elosulfase alfa is well-
tolerated and produces a decrease in uKS and a trend toward 
improvement in growth.
Morquio A syndrome is a rare inherited disorder caused by mutations of the gene that codes for the lysosomal 
enzyme N-acetylgalactosamine-6-sulfatase (GALNS, EC 
3.1.6.4), which degrades the glycosaminoglycans keratan sul-
fate (KS) and chondroitin sulfate (1,2). GALNS insufficiency 
leads to progressive accumulation of glycosaminoglycans in 
multiple tissues and organs. In turn, this accumulation leads 
to significant morbidities and multisystemic clinical impair-
ments causing diminished functional capacity, decreased 
endurance, impaired quality of life, and early mortality (3). The 
most apparent and most commonly reported clinical features 
of patients with Morquio A syndrome are progressive skeletal 
dysplasia and musculoskeletal abnormalities, typically associ-
ated with disproportionate short stature, short neck and trunk, 
and joint abnormalities (3–5). Although growth impairment 
is a major manifestation of Morquio A syndrome, growth is 
generally normal in very young patients and starts to decrease 
between the ages of 2 and 5 y, resulting in a mean adult stand-
ing height around 120 cm in men and 110 cm in women (4,6,7). 
Morquio A patients also commonly present with nonskeletal 
manifestations such as respiratory  dysfunction, cardiovascu-
lar abnormalities, cervical/thoracolumbar cord compression, 
vision and hearing impairment, dental abnormalities, and 
hepatosplenomegaly (3,5).
In 2014, recombinant human GALNS (elosulfase alfa, 
Vimizim; BioMarin Pharmaceutical, Novato) was approved as 
an enzyme replacement therapy (ERT) for patients with Morquio 
A syndrome in the United States, Europe, Canada, Australia, 
and Brazil (8) (http://investors.bmrn.com/releases.cfm). The 
pivotal randomized, double-blind, placebo-controlled phase III 
study showed significant improvement in the 6-min walk test 
distance (primary endpoint), a substantial reduction in urine 
KS (uKS), and numerical improvements in several exploratory 
endpoints, including respiratory function, height, and growth 
rate, with 2 mg/kg/week elosulfase alfa dosing (9,10). However, 
the phase III study, as well as a previous phase I/II dose-ranging 
study, only included patients of 5 y of age and older (9,11). This 
open-label study was designed to explore the safety and clinical 
activity of elosulfase alfa in Morquio A patients younger than 
5 y of age. Growth was selected as the major clinical endpoint 
of the study in order to assess if elosulfase alfa could prevent 
or minimize the deviation from the normal growth curve that 
generally occurs during these early years.
RESULTS
Patient Characteristics
Fifteen patients aged 9 mo to 4.9 y were enrolled in the study. 
All patients completed the primary treatment phase, and 
none permanently discontinued elosulfase alfa. Demographic 
and baseline data are presented in Table 1. Based on physical 
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examination findings at screening and reported medical his-
tory, the majority of patients had abnormal musculoskeletal 
features (93.3%), with knee deformities (66.7%), pectus cari-
natum (66.7%), kyphosis (60.0%), and dysmorphism (60%) 
most frequently reported. Other findings were abnormal gen-
eral appearance (60.0%), abnormal head, eyes, ears, nose, and 
throat (66.7%), corneal opacity (clouding) (33.3%), and deaf-
ness (53.3%). Cardiovascular abnormalities occurred in three 
(20%) patients and included mild to moderate mitral, pulmo-
nary, and/or tricuspid valve regurgitation and mitral and/or 
aortic valve thickening. Standing height (in patients ≥ 2 y) was 
severely affected, with almost half of patients (46.7%) below 
the third percentile of normal for age. Normalized uKS (mean 
35.9 μg/mg creatinine; Table 1) was elevated tenfold above the 
mean for a similar age control population (12).
Safety Results
All 15 enrolled patients were included in the safety analysis and 
completed 52 wk of treatment. The mean weekly dose received 
was 1.9 (±0.1) mg/kg/patient. Of 780 planned infusions, 37 
(4.7%) were missed in 12 (80.0%) patients. All patients had 
≥88% dosing compliance (100 × (actual dose/total planned 
dose)).
Table 2 summarizes the AEs reported during the 52 wk 
study. All 15 patients reported at least one AE. Eleven (73.3%) 
patients experienced at least one study drug-related AE. The 
most frequently reported drug-related AEs were pyrexia 
(40.0%) and vomiting (33.3%) (Table 2). Most AEs were mild 
or moderate in severity. Only one patient experienced severe 
events, i.e., routine tonsillectomy for enlarged tonsils and 
cervical cord compression, which was unrelated to the tonsil-
lectomy. Both events were not considered drug-related by the 
investigator. None of the children discontinued from the study 
due to AEs.
All 15 patients reported at least one infusion-associated reac-
tion (IAR) (any AE occurring after infusion onset and within 
1 d after infusion end, regardless of relation with study drug). 
All IARs were mild or moderate in severity and generally man-
ageable with symptomatic treatment. Six of the 743 infusions 
(0.8%) were interrupted (three infusions) or discontinued 
table 1. Demographics and baseline characteristics
Characteristics
Elosulfase 2.0 mg/
kg/wk (N = 15)
Age at enrollment (y)
  Mean (SD) 3.1 (1.3)
  Median 3.1
  Min, Max 0.8, 4.9
Age group (y), N (%)
  0 to < 3 y 7 (46.7)
  ≥ 3 to < 5 y 8 (53.3)
Sex, N (%)
  Female 8 (53.3)
  Male 7 (46.7)
Race, N (%)
  Asian 4 (26.7)
  White 10 (66.7)
  Other: East Asian/African American 1 (6.7)
Ethnicity, N (%)
  Hispanic or Latino 1 (6.7)
  Not Hispanic or Latino 14 (93.3)
Normalized uKSa (μg/mg)
  Mean (SD) 35.9 (12.3)
  Median 35.4
  Min, Max 18.8, 56.5
Length (cm)
  Mean (SD) 90.1 (9.3)
  Median 89.6
  Min, Max 75.8, 113.0
Standing heightb (cm)
  Mean (SD) 88.9 (9.0)
  Median 90.0
  Min, Max 72.3, 109.2
aNormalized urine keratan sulfate (uKS) is calculated as urine KS divided by urine creatinine. 
Normalized uKS level in healthy controls aged 0-6 y range between 0.42 and 5.7  µg/mg 
creatinine (12). bheight was not obtained for two of the subjects who were < 2 y of age.
table 2. Overall summary of AEs
Elosulfase alfa 2.0 mg/
kg/wk (N = 15)
Any AE 15 (100.0%)
  Grade 3 1 (6.7%)
Number of AE per subject: mean/median 27.7/25.0
Any study drug-relateda AE 11 (73.3%)
  Grade 3 0 (0.0%)
Most frequently reportedb drug-relateda AEs
  Pyrexia 6 (40.0%)
  Vomiting 5 (33.3%)
  Abdominal pain 3 (30%)
  Abdominal pain upper 3 (30%)
  Tachycardia 3 (30%)
Any SAE 4 (26.7%)
  Grade 3 1 (6.7%)
Any study drug-relateda SAE 1 (6.7%)
   Grade 3 0 (0.0%)
Any AE leading to study discontinuation 0 (0.0%)
Any AE leading to permanent study  
drug discontinuation
0 (0.0%)
Death 0 (0.0%)
AEs coded by MedDRA version 15.0; maximum severity is summarized by subject.
Severity based on CTCAE: grade 1 = mild; 2 = moderate; 3 = severe, disabling or limiting 
self care activities of daily living; 4 = life-threatening or debilitating; 5 = Death.
All AEs are treatment-emergent; subjects with more than one AE within a category 
were counted once.
AE, adverse event.
aA drug-related AE was classified by investigator as possibly or probably related to study 
drug. bOccurring in at least three patients (20%).
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(three infusions) due to an AE and required medical inter-
vention in three patients (20%). AEs that resulted in infusion 
interruptions and/or discontinuations could be managed with 
symptomatic treatment (oxygen, IV steroids, IV antihista-
mines, or IV fluids) and infusion rate adjustment. In all cases, 
patients were successfully redosed and tolerated subsequent 
infusions.
There were no life-threatening AEs (grade 4) or deaths. 
Four patients (26.7%) reported a total of eight serious AEs 
(SAEs), with only one assessed as related to the study drug. 
Supplementary Appendix S1 online provides more details 
about this SAE. Eight hypersensitivity AEs occurred in four 
(26.7%) patients (more details are provided in Supplementary 
Appendix S1 online).
No clinically meaningful changes in vital signs, electrocar-
diograms, echocardiograms, clinical chemistry, hematology, 
or urinalysis results were observed. No new or unexpected 
safety signals were observed and no expedited safety reports 
were required.
Elosulfase alfa total antibodies were detected in all patients by 
week 4 and remained positive throughout the study. No patients 
tested positive for drug-specific IgE. The number of patients 
with hypersensitivity AEs was too low to identify a relationship 
with total antibody titers. No apparent relationship was observed 
between total antibody titers and height z-score measurements. 
Reductions in uKS occurred and were maintained despite the 
development of antidrug antibodies. Patients with total anti-
body titers greater than the mean had similar decreases in uKS 
as patients with total antibody titers below the mean.
Efficacy Results
All 15 patients were included in the efficacy analyses. Elosulfase 
alfa substantially decreased the mean normalized uKS levels 
within 2 wk, which was maintained over 52 wk (Figure 1). The 
mean (±SD) percent change from baseline in uKS was −30.2% 
(±12.7) at 2 wk and −43.5% (±22.2) at 52 wk.
The mean weight (all patients) increased by 1.7 (±0.8) kg 
from baseline to week 52; a mean percent change of 13.8% 
(±7.3). The mean height in patients ≥2 y of age (N = 12) 
increased by 5.3 (±2.4) cm from baseline to week 52; a mean 
percent change of 5.9% (±2.5). In patients <2 y (N = 3), the 
mean length increased by 6.0 (±2.7) cm from baseline to week 
52; a mean percent change of 6.8% (±3.3). For all 15 patients, 
the mean height/length for age z-score was −1.6 (±1.6) at base-
line and −1.9 (±1.6) after 52 wk of treatment (Figure 2a). The 
mean change from baseline at 52 wk was −0.4 (±0.5). The mean 
height z-score for the 12 patients ≥2 y of age at baseline was 
−2.0 (±1.5), as compared to −2.2 (±1.3) in 24 untreated sub-
jects of similar age from the Morquio A Clinical Assessment 
Program (MorCAP) natural history study (1 of the 25 patients 
from the MorCAP study did not have a week 52 assessment). 
After 52 wk, height z-scores in both groups were −2.2 (±1.7) 
and −3.0 (±1.2), respectively (Figure 2b).
The mean growth rate z-score per year was −0.6 (± 0.6; N = 8) 
at baseline and −0.4 (±0.5; N = 15) at week 52. Cumulative 
growth rate change was computed for the eight patients for 
whom prestudy growth rate data were available. The mean 
change in growth rate from baseline to week 52 in these patients 
was 0.2 (±1.0) (Figure 2c). In patients ≥2 y of age, the mean 
normalized growth rate z-score was −0.8 (±0.8; N = 5) at base-
line and −0.3 (±0.5; N = 12) at week 52. Mean change in the 
patients with prestudy growth rate data was 0.6 (±1.1; N = 5).
DISCUSSION
Elosulfase alfa is currently the only approved drug therapy 
for Morquio A syndrome that directly targets the underlying 
cause of the disease. Previous studies have assessed the effi-
cacy and safety of elosulfase alfa in a wide age range, but not in 
patients younger than 5 y (9–11). The present study is the first 
to specifically examine the safety, tolerability, and pharmaco-
dynamic responses, as demonstrated by reduction of uKS, and 
impact on growth of elosulfase alfa in this young patient group.
Figure 1. Normalized urine keratan sulfate (uKS): mean percent change from baseline (N = 15). Normalized uKS is calculated as uKS divided by urine 
creatinine.
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Overall, the safety analysis of this study showed that admin-
istration of elosulfase alfa is generally well tolerated in patients 
aged <5 y. The study did not reveal any new unexpected safety 
issues that were not reported in previous studies including older 
patients (9–11). Overall dosing compliance was high, i.e., ≥88% 
for all patients, with only 37 of 780 infusions missed (< 5%). 
No patients permanently discontinued treatment due to an AE 
and infusions requiring interruption or discontinuation due to 
an AE and requiring medical intervention, such as IV antihis-
tamines or IV steroids, represented a small percentage of all 
743 infusions (0.8%). This is comparable to the phase III study 
with 1.3% of infusions interrupted or discontinued (9). Only 
one patient experienced a SAE that was considered related to 
elosulfase alfa (moderate hypersensitivity). This patient contin-
ued to receive subsequent infusions and completed the 52 wk 
of treatment without experiencing additional hypersensitivity 
events. All patients experienced at least one IAR, but these were 
mild to moderate in severity and generally manageable with 
symptomatic treatment. The most frequently reported drug-
related AEs (pyrexia, vomiting) were also IARs, similar to what 
was observed in the pivotal phase III study (9). Headache and 
nausea were less frequent in this study than in the phase III 
study (9). This may be related to the need to have appropriate 
language skills to verbalize and convey nausea and headache 
symptoms. Although all patients developed antidrug total anti-
bodies by week 4, there was no apparent relationship between 
total antibody titers and uKS or height z-score measurements. 
The same has been reported for older patients included in the 
phase III study (9). Although promising, the favorable tolerabil-
ity and safety data in this pediatric patient population should 
be interpreted cautiously due to certain limitations in the study 
design, including the open-label design and the limited sample 
size.
The efficacy analysis showed a substantial decrease in mean 
normalized uKS levels within 2 wk of treatment with elosulfase 
alfa, with the decreased levels being maintained over 52 wk. 
uKS is considered a pharmacodynamic biomarker for Morquio 
A syndrome with higher levels of uKS being associated with 
more severe clinical impairment (4,13). The observed decline 
in uKS of 43.5% was comparable to that reported for older 
children and adult patients in the elosulfase alfa phase I/II and 
phase III studies (9,11).
Skeletal abnormalities represent a major manifestation of 
Morquio A syndrome; however, young patients often do not 
possess, or have not yet developed, the severe abnormalities 
present in older patients. It is therefore postulated that early 
treatment may be particularly effective in changing the course of 
skeletal disease (4,6,7). Although there is currently limited data 
on younger patients, available data from natural history studies 
show that patients gradually fall off the anticipated growth tra-
jectory by 2 y of age (4,6,7). In MorCAP, a natural history study 
including 325 untreated patients with Morquio A syndrome, 
height z-scores in patients older than 5 y were approximately 
5–7 SDs below the normal range, while in younger patients, 
height was already decreasing by about 2 SDs below normal 
(4). These findings are consistent with the results of the current 
study in which the baseline mean normalized standing height 
z-score was −1.6. After 1 y of treatment, the mean z-score was 
only slightly lower (−1.9) and the mean normalized growth 
rate z-scores were numerically improved from baseline, indi-
cating a closer to normal growth rate on treatment. Impact of 
treatment on growth may be more appropriately evaluated if 
Figure 2. Normalized height/length and growth rate from baseline to 
week 52. (a) Mean standing height/lengtha z-score. Normalized standing 
height or length was computed using Centers for Disease Control normal 
values (17). (b) Mean standing height z-score at baseline and 52 wk for 
12 patients ≥2 y of age included in this study (upper line) compared with 
25 untreated subjects of 2–5 y of age included in the Morquio A Clinical 
Assessment Program (MorCAP) longitudinal natural history study at base-
line and 52 wk (lower line). One of the 24 patients from the MorCAP study 
did not have a week 52 assessment and was excluded from this analysis. 
(c) Mean growth rate (per year) for standing height/lengtha z-score. 
Baseline rate calculation was based on observations up to 2 y prior to 
study entry. aLength was measured instead of standing height in subjects 
<2 y of age (N = 3).
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disease-specific growth charts were used as they are currently 
available for other MPS disorders (14,15). Comparison of the 
current data with longitudinal growth data from the MorCAP 
study suggests that elosulfase alfa improves growth rates 
(Figure 2b). This finding is consistent with that of the phase III 
study where results suggested improved growth with treatment 
in individuals still growing (females <15 y and males <18 y) 
(10). However, as growth rates vary considerably during these 
years, a longer duration of follow-up will be needed to deter-
mine the significance of this early observation (16).
Corneal clouding, hearing loss/deafness, and cardiac valve 
abnormalities were common findings in the study popula-
tion, even in the younger children. The prevalence of these 
findings was strikingly similar to that reported previously 
in the pediatric patients included in the MorCAP study (4), 
which highlights the importance of regular follow-up and the 
need for and potential benefit of early intervention. It should 
be noted that the effect of early ERT on corneal clouding 
and cardiac valves is unclear due to the poor vascularity at 
these sites, and based on the experience with ERT in other 
mucopolysaccharidoses.
In conclusion, the results of this study suggest a favorable 
benefit/risk profile for elosulfase alfa in pediatric Morquio A 
patients less than 5 y of age. Early intervention with elosulfase 
alfa produced a decrease in urinary KS and seemed to have 
improved growth. The extension phase of this study will pro-
vide more comprehensive data on growth effects and other 
long-term benefits in these patients.
METHODS
Study Design
This study is an ongoing, phase II, open-label, multinational study 
consisting of an initial 52-wk primary treatment phase and an exten-
sion period of up to 156 wk plus 1 additional week for final study 
assessments. We report the results of the completed primary treat-
ment phase, of which the primary objective was to evaluate safety and 
tolerability of infusions of elosulfase alfa 2.0 mg/kg/week in Morquio 
A patients <5 y of age. The secondary objectives were to evaluate its 
ability to reduce uKS levels and to assess its impact on growth veloc-
ity. The dose of 2.0 mg/kg/week was selected from the analysis of 
study data from a phase I/II dose escalation study (11).
The study is being conducted by four investigators at four study 
centers in three countries (USA, UK, and Italy) in accordance with 
the United States Code of Federal Regulations and/or other national 
and local regulations, the ICH Harmonized Tripartite Guideline 
(Guideline for Good Clinical Practice E6) and the ethical principles 
established by the Declaration of Helsinki.
Patient Selection
Individuals eligible to participate in this study were <5 y of age at 
first infusion, had a documented clinical diagnosis of Morquio A 
syndrome based on reduced fibroblast or leukocyte GALNS enzyme 
activity or genetic testing confirming the diagnosis. Each patient’s 
parent or other legally authorized representative provided written 
informed consent before study onset. Exclusion criteria were previous 
hematopoietic stem cell transplantation or treatment with elosulfase 
alfa, known hypersensitivity to any of the components of elosulfase 
alfa, major surgery within 3 mo prior to study entry or planned major 
surgery during the initial treatment period, use of any investiga-
tional product or investigational medical device within 30 d prior to 
screening or requirement for any investigational agent prior to study 
completion, concurrent disease or condition that would interfere with 
study participation or safety (symptomatic cervical spine instability, 
clinically significant spinal cord compression, severe cardiac disease), 
and any condition that placed the patient at high risk of poor treat-
ment compliance or of not completing the study.
Study Drug Administration
All patients received pretreatment with an antihistamine within 1 h 
prior to each infusion. The choice of preinfusion medications was 
left to the discretion of the investigator. There was some minimal 
instruction to try nonsedating antihistamines first. Elosulfase alfa 
was diluted with sterile 0.9% sodium chloride (no standard source) 
at room temperature prior to administration and was infused IV over 
approximately 4 h, with vital signs monitored before, during, and after 
the infusion. Patients were also monitored by continuous pulse oxim-
etry during and for at least 60 min after the infusion. Supplementary 
Appendix S2 online provides more detailed infusion procedures.
Safety Evaluation
Supplementary Appendix S3 online provides a schedule of the most 
important safety and efficacy assessments done during the primary 
treatment phase. Safety was assessed by examining incidence, severity, 
and relationship to study drug of treatment-emergent adverse events 
reported during the study. A treatment-emergent adverse event was 
defined as any adverse event (AE) that was new, increased in frequency, 
or worsened in severity after the first dose of study drug, including 
AEs with missing onset dates. An AE assessed by the investigator as 
possibly or probably related to study drug documented in the elec-
tronic case report form was counted as drug-related. In addition, vital 
signs, physical examinations, laboratory results, electrocardiograms, 
echocardiograms, cervical spine radiographs, concomitant medica-
tions, and immunogenicity were assessed per protocol. Machine types 
for making electrocardiograms and radiographs were not specified 
and varied from center to center, but a full set of instructions on how 
to collect the images was provided by BioClinica (Newtown, PA).
The investigator determined the severity of each event using the 
National Cancer Institute Common Terminology Criteria for Adverse 
Events v. 4.0. Hypersensitivity AEs were identified by utilizing the 
broad algorithmic Anaphylactic Reaction Standardized MedDRA 
Query (SMQ) v. 15.0 and the broad Angioedema SMQ. IARs were 
defined as all AEs (regardless of drug relationship) that occurred after 
infusion onset and within 1 d after infusion end.
Immunogenicity tests were performed using validated immunoge-
nicity assays on blood samples and included a total antidrug antibody 
test (BioMarin Pharmaceutical), and drug-specific (anti-rhGALNS) 
IgE and total IgE tests (Viracor-IBT Laboratories, Lee’s Summit, MO).
Efficacy Evaluation
uKS levels (normalized to creatinine) were measured by liquid chro-
matography followed by tandem mass spectrometry (Pacific BioLabs, 
Hercules, CA) (see Supplementary Appendix S3 online for schedule 
of assessments) (12). Normalized standing height or length was com-
puted using the Centers for Disease Control norms (see Supplementary 
Appendix S4 online for details on method) (17). Growth rate change was 
calculated as on-study growth rate (GR1S)–prestudy growth rate (GR0) for 
patients who had growth measurements within 2 y prior to study entry, 
with GR0 = (Zbaseline − Zprestudy)/T and GR1S = (ZS − Zbaseline)/T; where Zbaseline 
is the standing height/length z-score measured at baseline, Zprestudy the 
z-score closest to, but not greater than, 2 y prior to study entry, ZS the 
z-score measured at weeks 13, 26, 39, and 52, and T the time (in years) 
between corresponding measurements. All anthropometric measure-
ments and growth rates were analyzed among all patients and for the 
subset of patients ≥2 y of age. Finally, mean height z-scores of the patients 
aged ≥2 y (Centers for Disease Control height measurements start at 2 y 
vs. length below this age) were compared to those of 25 untreated patients 
included in the MorCAP natural history study (4). These untreated 
patients were of similar age (2–5 y old) at baseline and at 52 wk. Baseline 
age, height, weight, and distribution of gender were similar between 
treated and untreated groups (Supplementary Appendix S5 online).
Statistical Methods
This paper reports the results of the completed 52-wk primary treat-
ment phase. Safety and tolerability of elosulfase alfa was the primary 
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endpoint. Secondary endpoints were change in uKS and growth 
velocity over 52 wk. The efficacy population consisted of all patients 
who received ≥1 dose of study drug and had ≥1 postbaseline efficacy 
measurement. The safety population consisted of all patients who 
received any study drug throughout the study duration. Compliance 
was derived from the total amount of study drug intake (actual dose) 
divided by the planned study drug intake during the study period 
(total planned dose), and multiplied by 100%.
Descriptive statistical summaries of continuous variables were 
done using SAS (r) Proprietary Software 9.2 (TS2M0) (SAS Institute, 
Cary, NC) and included the mean, SD, median, and range. Descriptive 
summaries of categorical variables included sample size and percent. 
Z-score height/length was compared to 25 patients of MorCAP who 
were aged 2–5 at entry to the MorCAP study. Patients in MorCAP had 
annual anthropometric assessments; however, there was some vari-
ability around the timing of the visit and the first annual follow-up 
score was linearly interpolated to precisely 365 d postbaseline.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/pr
ACKNOWLEDGMENTS
We acknowledge the participation of study patients and their families 
and the expert assistance of all study site coordinators and personnel. The 
authors are also grateful to Ismar Healthcare NV for support in the process 
of manuscript development, and to the Manchester National Institute for 
Health Research/Wellcome Trust Clinical research facility.
STATEMENT OF FINANCIAL SUPPORT
This study was sponsored by BioMarin Pharmaceutical Inc., Novato, CA, USA 
and supported, in part, by the National Center for Advancing Translational 
Sciences, National Institutes of Health, Bethesda, MD, USA through UCSF-
CTSI Grant Number UL1 TR000004 (P.H.). Its contents are solely the respon-
sibility of the authors and do not necessarily represent the official views of 
the NIH.
Disclosure: S.A.J., P.H., M.B., and R.P. are primary investigators for this trial. 
P.H. is a consultant and speaker for BioMarin and has received grant support 
from BioMarin. R.P. is a consultant and speaker for BioMarin. S.A.J. is a con-
sultant/speaker for BioMarin and has received travel support. K.M., K.Y., and 
A.J.S. are employees and stock owners of BioMarin. H.W. is a consultant for 
BioMarin. The study design, collection, analysis and interpretation of data, 
the preparation of this manuscript, and the decision to submit the paper for 
publication were supported by BioMarin Pharmaceutical Inc.
REFERENCES
 1. Tomatsu S, Montaño AM, Nishioka T, et al. Mutation and polymorphism 
spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). 
Hum Mutat 2005;26:500–12.
 2. Morrone A, Tylee KL, Al-Sayed M, et al. Molecular testing of 163 patients 
with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS 
mutations. Mol Genet Metab 2014;112:160–70.
 3. Tomatsu S, Montaño AM, Oikawa H, et al. Mucopolysaccharidosis type 
IVA (Morquio A disease): clinical review and current treatment. Curr 
Pharm Biotechnol 2011;12:931–45.
 4. Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A Clinical Assess-
ment Program: baseline results illustrating progressive, multisystemic 
clinical impairments in Morquio A subjects. Mol Genet Metab 2013;109: 
54–61.
 5. Hendriksz CJ, Al-Jawad M, Berger KI, et al. Clinical overview and treat-
ment options for non-skeletal manifestations of mucopolysaccharidosis 
type IVA. J Inherit Metab Dis 2013;36:309–22.
 6. Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International 
Morquio A Registry: clinical manifestation and natural course of Morquio 
A disease. J Inherit Metab Dis 2007;30:165–74.
 7. Montaño  AM, Tomatsu  S, Brusius  A, Smith  M, Orii  T. Growth charts 
for patients affected with Morquio A disease. Am J Med Genet A 
2008;146A:1286–95.
 8. Sanford  M, Lo  JH. Elosulfase alfa: first global approval. Drugs 2014;74: 
713–8.
 9. Hendriksz CJ, Burton B, Fleming TR, et al.; STRIVE Investigators. Efficacy 
and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) 
for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 ran-
domised placebo-controlled study. J Inherit Metab Dis 2014;37:979–90.
 10. Hendriksz CJ, Giugliani R, Harmatz P, et al.; STRIVE Investigators. Multi-
domain impact of elosufase alfa in Morquio A syndrome in the pivotal 
phase III trial. Mol Genet Metab 2015;114:178–85.
 11. Hendriksz C, Vellodi A, Jones S, et al. Long term outcomes of a phase 1/2, 
multicenter, open-label, dose-escalation study to evaluate the safety, toler-
ability, and efficacy of BMN 110 in patients with mucopolysaccharidosis 
IVA (Morquio A syndrome). Mol Genet Metab 2012;105:S35.
 12. Martell LA, Cunico RL, Ohh J, Fulkerson W, Furneaux R, Foehr ED. Vali-
dation of an LC-MS/MS assay for detecting relevant disaccharides from 
keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis 
2011;3:1855–66.
 13. Dũng  VC, Tomatsu  S, Montaño  AM, et al. Mucopolysaccharidosis IVA: 
correlation between genotype, phenotype and keratan sulfate levels. Mol 
Genet Metab 2013;110:129–38.
 14. Quartel A, Hendriksz CJ, Parini R, Graham S, Lin P, Harmatz P. Growth 
Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy 
Syndrome). JIMD Rep 2015;18:1–11.
 15. de Ruijter  J, Broere L, Mulder MF, et al. Growth in patients with muco-
polysaccharidosis type III (Sanfilippo disease). J Inherit Metab Dis 
2014;37:447–54.
 16. Tanner  JM, Whitehouse  RH. Clinical longitudinal standards for height, 
weight, height velocity, weight velocity, and stages of puberty. Arch Dis 
Child 1976;51:170–9.
 17. Kuczmarski RJ, Ogden CL, Guo SS et al. 2000 CDC Growth Charts for the 
United States: methods and development. Vital Health Stat 11 2002;1–190.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 
 International License. The images or other third party  material 
in this article are included in the article’s Creative Commons 
license, unless indicated otherwise in the credit line; if the ma-
terial is not included under the Creative  Commons license, us-
ers will need to obtain permission from the license holder to 
reproduce the material. To view a copy of this license, visit 
http://creativecommons.org/licenses/by-nc-nd/4.0/
722 Pediatric RESEARCh     Volume 78  |  Number 6  |  December 2015
